Observational study / 2020
Regular glucosamine supplementation was linked to lower risks of all-cause and cause-specific mortality in a large UK cohort.
This prospective cohort study evaluated 495,077 participants from the UK Biobank followed for a median of 8.9 years to assess links between regular glucosamine supplement use and mortality. During follow-up, 19,882 all-cause deaths occurred. In multivariable-adjusted models, glucosamine use was associated with hazard ratios of 0.85 (95% CI 0.82 to 0.89) for all-cause, 0.82 (95% CI 0.74 to 0.90) for CVD, 0.94 (95% CI 0.88 to 0.99) for cancer, 0.73 (95% CI 0.66 to 0.81) for respiratory, and 0.74 (95% CI 0.62 to 0.90) for digestive disease mortality. The inverse association with all-cause mortality appeared somewhat stronger among current smokers than non-current smokers (p for interaction = 0.00080).
Shows an association, not proof of cause and effect.
- Study type
- Prospective cohort study
- Who was studied
- 495,077 women and men from the UK Biobank (mean age 56.6 years)
- What was measured
- All-cause mortality and mortality due to cardiovascular disease, cancer, respiratory, and digestive disease
THE PAPER
Associations of regular glucosamine use with all-cause and cause-specific mortality: a large prospective cohort study.
Li ZH, Gao X, Chung VC, Zhong WF, Fu Q, Lv YB, Wang ZH, Shen D, Zhang XR, Zhang PD, Li FR, Huang QM, Chen Q, Song WQ, Wu XB, Shi XM, Kraus VB, Yang X, Mao C. Ann Rheum Dis, 2020.
This note is written from the study's published abstract. It summarizes what the authors reported; it is not medical advice and does not replace reading the full paper.